Clinical Trials Logo

Smoldering Multiple Myeloma clinical trials

View clinical trials related to Smoldering Multiple Myeloma.

Filter by:

NCT ID: NCT05831358 Recruiting - Multiple Myeloma Clinical Trials

Early Detection of Multiple Myeloma to Fight Cancer Disparities: A Screening and Patient Navigation Program

Start date: June 16, 2023
Phase: N/A
Study type: Interventional

This project will pilot the expansion of the existing Taussig Outreach Program's community outreach and patient navigation model to study the multiple myeloma (MM) screening program. This involves analyzing community reception, screening program methods, reasons patients decided to participate, reasons patients declined participation, and participant views and attitudes. This study also aims to gauge the current and general understanding of MM. This study seeks to recruit participants in the pilot screening program to promote early detection. Participants who have abnormal results will receive patient navigation for further diagnostics and testing.

NCT ID: NCT05767359 Recruiting - Multiple Myeloma Clinical Trials

CAR- PRISM (PRecision Intervention Smoldering Myeloma)

Start date: April 19, 2023
Phase: Phase 2
Study type: Interventional

The goal of this research study is to test if ciltacabtagene autoleucel (cilta-cel) is safe and effective in treating participants with high-risk, smoldering myeloma. The names of the treatment interventions used in this study are: - Cilta-cel (or chimeric antigen receptor T cells) - Cyclophosphamide (a lymphodepleting chemotherapy) - Fludarabine (a lymphodepleting chemotherapy)

NCT ID: NCT05640843 Recruiting - Multiple Myeloma Clinical Trials

A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)

Start date: November 29, 2022
Phase: N/A
Study type: Interventional

The researchers are doing this study to look at how butyrate levels change in participants' stool after they are on a- plant-based diet for at least 12 weeks. All participants will have monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM). We will compare how the plant-based diet, omega-3 fatty acid and curcumin supplements, and placebo (an inactive substance that looks like the study supplements) affect butyrate levels in participants' stool.

NCT ID: NCT05597345 Recruiting - Clinical trials for Smoldering Multiple Myeloma

Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma

Start date: August 21, 2023
Phase: Phase 2
Study type: Interventional

Selinexor is a drug that has been approved in the treatment of patients with symptomatic multiple myeloma. The standard of care for patients with Smoldering Multiple Myeloma remains observation, but there are numerous clinical trials investigating interventions to delay progression to multiple myeloma and prevent or delay disease related outcomes. A subset of patients with intermediate or high risk smoldering multiple myeloma have a much higher risk of progressive to multiple myeloma, while the low risk smoldering myeloma patient population has a much lower risk. This is a clinical trial investigating the use of low-dose selinexor in patients with intermediate to high-risk smoldering multiple myeloma. The investigators hypothesize that the use of selinexor in intermediate to high risk smoldering myeloma patients will help to delay progression of disease to symptomatic multiple myeloma.

NCT ID: NCT05469893 Recruiting - Multiple Myeloma Clinical Trials

Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

Start date: August 10, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test the anti-cancer activity of Teclistamab and to compare it with Lenalidomide + Dexamethasone combination in people with high risk smoldering multiple myeloma. People with smoldering multiple myeloma (SMM) usually do not have symptoms but are at risk for progressing to active multiple myeloma (MM). Multiple Myeloma is a cancer of the plasma cells, which are an important part of the immune system. Patients with active multiple myeloma generally require treatment but there are currently no approved therapies for smoldering multiple myeloma. The names of the study drugs involved in this study are: - Teclistamab - Lenalidomide (also called Revlimid) - Dexamethasone (also called Decadron)

NCT ID: NCT05361694 Recruiting - Multiple Myeloma Clinical Trials

Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions

TRANSFORMM
Start date: April 12, 2022
Phase:
Study type: Observational

The key aim of the study is to define the two biologically and clinically distinct entities: progressive versus stable myeloma precursor conditions.

NCT ID: NCT05312255 Recruiting - Plasma Cell Myeloma Clinical Trials

Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma

Start date: June 28, 2022
Phase: N/A
Study type: Interventional

This clinical trial investigates the effect of non-chemotherapeutic interventions in patients with multiple myeloma. Non-chemotherapeutic interventions such as physical activity and nutritional interventions (e.g., modifications in diet) have been shown to positively affect the immune system and improve overall quality of life. Another purpose of this study is for researchers to learn how the addition of a beta-blocker (propranolol) to the standard treatment regimen in patients with newly diagnosed multiple myeloma affects immune response and quality of life. A study from the Mayo Clinic looked at multiple myeloma patients who were on a beta-blocker while undergoing chemotherapy and found that the use of a beta-blocker resulted in improved patient survival outcomes. Non-chemotherapeutic treatment options may help decrease symptoms and improve quality of life for patients with multiple myeloma.

NCT ID: NCT05288062 Active, not recruiting - Plasma Cell Myeloma Clinical Trials

Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma

Start date: March 22, 2022
Phase: Phase 2
Study type: Interventional

This phase II trial studies the effect of immunomodulatory drug(s) in combination with a corticosteroid drug in treating patients with multiple myeloma or smoldering multiple myeloma. Immunomodulatory drugs such as lenalidomide and pomalidomide work through a variety of mechanisms to affect the function of the immune system. They are widely used as treatment for multiple myeloma and remain the backbone of therapy for both newly diagnosed patients and patients that have multiple myeloma that has come back after treatment (relapsed). Corticosteroid drugs like dexamethasone are strong anti-inflammatory agents that are also widely used to treat patients with multiple myeloma. This study may help doctors find out how patients respond to one treatment cycle of immunomodulatory drug(s) in combination with dexamethasone. This may help doctors determine which combinations of drugs work best in treating patients with multiple myeloma or smoldering multiple myeloma.

NCT ID: NCT05283993 Recruiting - Multiple Myeloma Clinical Trials

A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH

Start date: July 1, 2021
Phase:
Study type: Observational

The primary aim is to establish a prospective cohort of patients with plasma cell disorders (PCDs). All of the hospitalized PCD patients who are willing to sign the informed consent form (ICF) will be included in this study. Clinical characteristics, treatment options and responses will be collected. Peripheral blood, bone marrow aspirate and urine samples before and after the treatment will banked for future research. Our team will focus on the clinical and pathological features of PCDs, the correlation between the minimal residual disease (MRD) status and prognosis, and the role of Tumor Microenvironment (TME) in the pathogenesis and progress of PCDs.

NCT ID: NCT05136807 Recruiting - Clinical trials for Monoclonal Gammopathy of Undetermined Significance

Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies

Start date: June 7, 2016
Phase:
Study type: Observational

This study examines the quality of life in patients with monoclonal gammopathy of unknown significance and smoldering multiple myeloma. Collecting quality of life information from patients may help doctors learn more about the most common symptoms and concerns patients with monoclonal gammopathy of unknown significance and smoldering multiple myeloma may have.